NDAORALTABLET
Approved
May 1942
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
12
Data completeness
5/8 — Partial
PREMARIN (estrogens, conjugated) by Pfizer is estrogen receptor agonists [moa]. Approved for moderate to severe vasomotor symptoms due to menopause, moderate to severe vulvar, vaginal atrophy due to menopause () and 10 more indications. First approved in 1942.
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PREMARIN is a conjugated estrogen oral tablet that acts as an estrogen receptor agonist to treat moderate to severe vasomotor symptoms and vaginal atrophy due to menopause, as well as hypoestrogenism and select cancers. It is one of the oldest hormone replacement therapies, approved in 1942, derived from pregnant mare urine. The drug works by binding to estrogen receptors to restore hormonal balance and alleviate menopausal symptoms.
LOE Approaching
As a legacy oral hormone therapy approaching loss of exclusivity, commercial roles focus on defending market share against newer delivery systems and managing transition to generic competition.
Mechanism of Action
Estrogen Receptor Agonists
Pharmacologic Class:
Estrogen
Worked on PREMARIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.